Regeneron’s Q2 2026 results surpassed analyst expectations, fueled by strong demand for its high-dose Eylea eye therapy.
Regeneron Pharmaceuticals (REGN) saw its shares rise in premarket trading after reporting Q2 2026 earnings that exceeded Wall Street estimates. The beat was primarily driven by robust sales of the high-dose version of its eye treatment, Eylea.
Analysts had anticipated a solid quarter, but the company outperformed expectations, reflecting strong demand for its flagship therapy. Eylea remains a key revenue driver for Regeneron, with the high-dose formulation contributing significantly to the quarter’s results.
The positive earnings report underscores Regeneron’s ability to maintain growth in its core therapeutic areas amid competitive pressures in the pharmaceutical sector.